TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

N C Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.